|Mr. Jigar Raythatha||Pres, CEO & Director||637.13k||N/A||N/A|
|Ms. Emma Reeve||Sr. VP, CFO, Treasurer & Sec.||645.96k||N/A||1961|
|Dr. Adrian M. Senderowicz M.D.||Sr. VP & Chief Medical Officer||555.06k||N/A||1964|
|Dr. Danny Reinberg Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Yang Shi Ph.D.||Co-Founder||N/A||N/A||N/A|
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Constellation Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 9.